Caliway Unveils Dual-Track Strategy with FDA Clearance for CBL-0302 Study

Caliway Announces FDA Clearance for CBL-0302

Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company, has recently secured clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application concerning CBL-0302. This approval marks the initiation of the second pivotal Phase 3 clinical study for CBL-514, a drug aimed at reducing localized fat, particularly in the abdomen.

Overview of the Study

CBL-0302, referenced as SUPREME-02, has successfully completed the FDA's review process, allowing for patient enrollment to commence shortly. The study design is rigorous, featuring a randomized, double-blind, placebo-controlled methodology across several countries, including the United States, Canada, and Australia. Roughly 320 participants will engage in the study, which aims to provide significant insights into CBL-514's efficacy, safety, and tolerability. The expected timeline for topline results is scheduled for 2027.

The primary efficacy of CBL-0302 will be measured using two key methods: a change in abdominal subcutaneous fat volume as assessed by MRI and the improvement in abdominal fat levels through the Patient-Reported Abdominal Fat Rating Scale (PR-AFRS). This dual approach is distinctive in its quantitative assessment, setting CBL-514 apart from other products in the aesthetic medicine market that often rely on subjective performance metrics.

Global Expansion

In parallel with its global commitment, Caliway is accelerating its clinical strategy in the Asia-Pacific region. Recently, the Taiwan Food and Drug Administration (TFDA) approved the Asia-Pacific Phase 2 study, CBL-0206, which is designed to operate alongside the global study. This trial has already gained approval from Australia's Human Research Ethics Committee (HREC) and plans to enroll around 250 participants between Taiwan and Australia.

CBL-0206 also implements a randomized, placebo-controlled design, further refining its efficacy assessments through both MRI and the PR-AFRS, synchronized with the global objectives for CBL-514.

Importance of the Study

Caliway's proactive approach signifies its strategy of merging global and regional perspectives in clinical research, emphasizing the need to establish a robust regulatory foundation for CBL-514. By including diverse demographic participation—especially with the focus on Asian populations—Caliway's research aims to broaden the data pool surrounding fat reduction therapies from CBL-514, paving the way for future expanding international markets and clinical applications.

Future Plans

Looking ahead, Caliway has intentions of submitting a Phase 3 clinical study application for another variant, CBL-0304, in China later in 2026. This continuous development underlines Caliway’s commitment to establishing CBL-514 as a forefront treatment in the global aesthetic medicine landscape.

About CBL-514

CBL-514 represents a pioneering approach to localized fat reduction, functioning as a first-in-class 505(b)(1) small-molecule injectable therapy. Unlike many existing treatments, CBL-514 aims to induce the apoptosis of fat cells without imposing systemic risks, showcasing an impressive tolerability profile throughout its trials.

Caliway has already conducted 10 clinical trials with over 544 subjects involved, successfully achieving all primary safety and efficacy endpoints. CBL-514 will be further refined for numerous indications, including moderate to severe cellulite and non-surgical localized fat reduction, indicating its extensive market potential.

Caliway Biopharmaceuticals is on a mission to redefine aesthetic medicine through innovative small-molecule therapeutics, aiming to assert itself as a leader in the sector. For more details on their initiatives and products, visit Caliway Biopharmaceuticals Official Website.